International consensus on lung function testing during the COVID-19 pandemic and beyond
- PMID: 35261912
- PMCID: PMC8607240
- DOI: 10.1183/23120541.00602-2021
International consensus on lung function testing during the COVID-19 pandemic and beyond
Abstract
Coronavirus disease 2019 (COVID-19) has negatively affected the delivery of respiratory diagnostic services across the world due to the potential risk of disease transmission during lung function testing. Community prevalence, reoccurrence of COVID-19 surges and the emergence of different variants of SARS-CoV-2 have impeded attempts to restore services. Finding consensus on how to deliver safe lung function services for both patients attending and for staff performing the tests are of paramount importance. This international statement presents the consensus opinion of 23 experts in the field of lung function and respiratory physiology balanced with evidence from the reviewed literature. It describes a robust roadmap for restoration and continuity of lung function testing services during the COVID-19 pandemic and beyond. Important strategies presented in this consensus statement relate to the patient journey when attending for lung function tests. We discuss appointment preparation, operational and environmental issues, testing room requirements including mitigation strategies for transmission risk, requirement for improved ventilation, maintaining physical distance and use of personal protection equipment. We also provide consensus opinion on precautions relating to specific tests, filters, management of special patient groups and alternative options to testing in hospitals. The pandemic has highlighted how vulnerable lung function services are and forces us to re-think how long-term mitigation strategies can protect our services during this and any possible future pandemic. This statement aspires to address the safety concerns that exist and provide strategies to make lung function tests and the testing environment safer when tests are required.
Copyright ©The authors 2022.
Conflict of interest statement
Conflict of interest: A. McGowan has nothing to disclose. Conflict of interest: P. Laveneziana reports personal fees from Novartis France, Chiesi France and Boehringer France, outside the submitted work. Conflict of interest: S. Bayat has nothing to disclose. Conflict of interest: N. Beydon has nothing to disclose. Conflict of interest: P.W. Boros has nothing to disclose. Conflict of interest: F. Burgos reports participation on a scientific advisory board for Medical Graphics Coorporation Diagnostics. Conflict of interest: M. Fležar has nothing to disclose. Conflict of interest: M. Franczuk reports personal fees from AstraZeneca, Boehringer Ingelheim and Chiesi, outside the submitted work. Conflict of interest: M-A. Galarza has nothing to disclose. Conflict of interest: A.H. Kendrick has nothing to disclose. Conflict of interest: E. Lombardi reports nonfinancial support from AbbVie, personal fees from Angelini and Boehringer, personal fees and nonfinancial support from Chiesi, personal fees from GSK, nonfinancial support from Lusofarmaco, personal fees and nonfinancial support from Novartis, personal fees from Omron, grants and nonfinancial support from Restech, grants and personal fees from Sanofi, personal fees and nonfinancial support from Vertex, and personal fees from Vifor, outside the submitted work. Conflict of interest: J. Makonga-Braaksma has nothing to disclose. Conflict of interest: M.C. McCormack reports royalties from UpToDate, and personal fees from Vera Med, GlaxoSmithKline and Celgene, outside the submitted work. Conflict of interest: L. Plantier has nothing to disclose. Conflict of interest: S. Stanojevic has nothing to disclose. Conflict of interest: I. Steenbruggen has nothing to disclose. Conflict of interest: B. Thompson has nothing to disclose. Conflict of interest: A.L. Coates has nothing to disclose. Conflict of interest: J. Wanger has nothing to disclose. Conflict of interest: D.W. Cockcroft reports participation on a medical advisory board for Pharmaxis. Conflict of interest: B. Culver has nothing to disclose. Conflict of interest: K. Sylvester has nothing to disclose. Conflict of interest: F. de Jongh has nothing to disclose.
Figures




Similar articles
-
[Standard technical specifications for methacholine chloride (Methacholine) bronchial challenge test (2023)].Zhonghua Jie He He Hu Xi Za Zhi. 2024 Feb 12;47(2):101-119. doi: 10.3760/cma.j.cn112147-20231019-00247. Zhonghua Jie He He Hu Xi Za Zhi. 2024. PMID: 38309959 Chinese.
-
The future of Cochrane Neonatal.Early Hum Dev. 2020 Nov;150:105191. doi: 10.1016/j.earlhumdev.2020.105191. Epub 2020 Sep 12. Early Hum Dev. 2020. PMID: 33036834
-
Practice recommendations for lung cancer radiotherapy during the COVID-19 pandemic: An ESTRO-ASTRO consensus statement.Radiother Oncol. 2020 May;146:223-229. doi: 10.1016/j.radonc.2020.04.001. Epub 2020 Apr 6. Radiother Oncol. 2020. PMID: 32342863 Free PMC article.
-
Resuscitation of Drowned Persons During the COVID-19 Pandemic: A Consensus Statement.JAMA Netw Open. 2022 Feb 1;5(2):e2147078. doi: 10.1001/jamanetworkopen.2021.47078. JAMA Netw Open. 2022. PMID: 35133441
-
Recovery of endoscopy services in the era of COVID-19: recommendations from an international Delphi consensus.Gut. 2020 Nov;69(11):1915-1924. doi: 10.1136/gutjnl-2020-322329. Epub 2020 Aug 14. Gut. 2020. PMID: 32816921 Review.
Cited by
-
[Risk Management in Performing Post-Pandemic Pulmonary Function Tests].Open Respir Arch. 2025 Jun 24;7(3):100459. doi: 10.1016/j.opresp.2025.100459. eCollection 2025 Jul-Sep. Open Respir Arch. 2025. PMID: 40746510 Free PMC article. Spanish.
-
Telemedicine and virtual respiratory care in the era of COVID-19.ERJ Open Res. 2022 Jul 25;8(3):00111-2022. doi: 10.1183/23120541.00111-2022. eCollection 2022 Jul. ERJ Open Res. 2022. PMID: 35891622 Free PMC article. Review.
-
Respiratory functions, respiratory muscle strength and fatigue in patients with pediatric-onset multiple sclerosis: a comparative cross-sectional study.Acta Neurol Belg. 2025 Feb;125(1):69-75. doi: 10.1007/s13760-024-02628-4. Epub 2024 Aug 21. Acta Neurol Belg. 2025. PMID: 39168946
-
What Have We Learned About Transmission of Coronavirus Disease-2019: Implications for Pulmonary Function Testing and Pulmonary Procedures.Clin Chest Med. 2023 Jun;44(2):215-226. doi: 10.1016/j.ccm.2022.11.005. Epub 2022 Nov 22. Clin Chest Med. 2023. PMID: 37085215 Free PMC article. Review.
-
Lung Function Tests in Infants and Children.Indian J Pediatr. 2023 Aug;90(8):790-797. doi: 10.1007/s12098-023-04588-8. Epub 2023 Jun 1. Indian J Pediatr. 2023. PMID: 37261706 Free PMC article. Review.
References
-
- McGowan A, Sylvester K,et al. . Lung function testing during COVID-19 pandemic and beyond. Recommendation from ERS Group 9.1 [Respiratory function technologists/scientists] ERS Group 9.1, May 2020. https://ers.app.box.com/s/zs1uu88wy51monr0ewd990itoz4tsn2h
-
- Thompson B, Warner J. P eak Respiratory Bodies recommend suspension of lung function testing. The Thoracic Society of Australia & New Zealand and Australian and New Zealand Society of Respiratory Science Ltd, 2020. https://nwmphn.org.au/wp-content/uploads/2020/10/peak_respiratory_bodies.... Accessed June 2020
-
- ARTP COVID-19 Group. Respiratory function testing during endemic COVID-19. www.artp.org.uk/write/MediaUploads/Standards/COVID19/Respiratory_Functio... Date last updated: 26 May 2020.
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous